We are a Chinese company so we really want to benefit Chinese patients and meet unmet medical needs in China. Otherwise, why would we start a…
In Conversation
Cell culture technology is the core for bio-manufacturing, not only recombinant proteins but any biologicals, including vaccines as well as gene and cell therapies!
Looking at our portfolio mix and our operations, we can see that the biotech boom in China is really driving demand for new solutions
Paradoxically, I believe you can find the most opportunities when the environment is complicated or difficult. This is why I decided to start a biotech company…
The Chinese biotech industry itself is already moving at supersonic speeds to catch up to international norms but I think Adlai Nortye is running even faster
Novartis has been present in China for the last three decades, during which we launched about 62 medicines (including different indications)
The idea is that we take the hidden gems available globally – in the areas of dermatology, medical aesthetics and other skin-related areas that affect people’s…
BioDuro 4.0 is really about explosive growth. Tangibly, in three years, we are looking to double our current size in both China and the US
The local Chinese industry has a history of working with generics and biosimilars, which is a matter of ‘reverse-engineering’. We are working to change this focus…
The CAR-T industry is still in its infancy and I realized there were still many imperfections with the technology
We are taking a well-established international model of elderly care and bringing it into China, where there is a great need for such elderly care
China, while the second-largest market in the world, is still not a mature market. Most of the multinational pharma affiliates here have only been fully present…
